Back

Rational Design of Immunogenic Nanoparticles as a Platform for Enhanced Ovarian Cancer Immunotherapy in Mice

Tang, L.; Marwedel, B.; Dang, C.; Olewine, M.; Jun, M.; Naydenkov, P.; Medina, L. Y.; Gayoso, V.; Doan, N.; OLeary, S. L.; Schiavone, C.; Cave, J.; Howard, T.; Watt, J. D.; Dogra, P.; Serda, R. E.; Noureddine, A.

2025-06-09 immunology
10.1101/2025.06.05.657862 bioRxiv
Show abstract

Ovarian cancer immunotherapy remains a challenge based on the "cold" tumor microenvironment. Herein we present a rational design to create immunogenic nanoparticles as a multi-agent platform that promotes immune response in a mouse model of ovarian cancer. The hybrid lipid-silica nanosystem is capable of co-loading four types of cargo molecules including a model antigen, nucleic acid-based adjuvant Cytosine-p-linked to Guanine (CpG, TLR3/9 agonist), lipid-based adjuvant (MPLA, TLR4 agonist) integrated into the lipid coat, and optionally a small molecule drug, such as the chemotherapeutic agent oxaliplatin, a well-established treatment for ovarian cancer. The optimization of the nanoplatform in terms of lipid composition, functionalized silica dendritic core formation, and final charge, as well as their compatibility with the complex loading profile highlights an opportunity for enhanced survival of mice with advanced ovarian cancer compared to monotherapy. Furthermore, intraperitoneal administration led to preferential accumulation within tumor-burdened tissues with selective accumulation in myeloid cells. High myeloid cell cytotoxicity negated the benefits of oxaliplatin. The inclusion of CpG in the nanoparticle formulation enhanced the survival of mice with ovarian cancer. To interpret these outcomes and guide future design, we also developed a mathematical model of nanoparticle-driven immune activation, which quantified treatment efficacy and identified key parameters governing tumor response. The presented hybrid nanoparticle i tunable, enabling delivery of alternative molecules therefore, thereby highlighting a promising platform for the treatment of peritoneal cancers. Graphical TOC O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=69 SRC="FIGDIR/small/657862v1_ufig1.gif" ALT="Figure 1000"> View larger version (26K): org.highwire.dtl.DTLVardef@1434599org.highwire.dtl.DTLVardef@18e79e6org.highwire.dtl.DTLVardef@e5285corg.highwire.dtl.DTLVardef@bcc604_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Advanced Functional Materials
41 papers in training set
Top 0.1%
18.9%
2
Journal of Controlled Release
39 papers in training set
Top 0.1%
15.0%
3
Nanoscale Advances
13 papers in training set
Top 0.1%
12.5%
4
Biomaterials Science
21 papers in training set
Top 0.1%
4.9%
50% of probability mass above
5
ACS Nano
99 papers in training set
Top 0.8%
4.4%
6
Biomaterials Advances
20 papers in training set
Top 0.2%
3.1%
7
ACS Biomaterials Science & Engineering
37 papers in training set
Top 0.3%
2.9%
8
Advanced Materials
53 papers in training set
Top 0.9%
2.1%
9
ACS Applied Bio Materials
21 papers in training set
Top 0.2%
1.9%
10
Small
70 papers in training set
Top 0.4%
1.7%
11
Nanoscale
39 papers in training set
Top 0.2%
1.4%
12
Advanced Biology
29 papers in training set
Top 0.6%
1.2%
13
Advanced Science
249 papers in training set
Top 14%
1.2%
14
Advanced Therapeutics
15 papers in training set
Top 0.3%
1.2%
15
ChemBioChem
50 papers in training set
Top 0.8%
1.2%
16
Molecular Pharmaceutics
16 papers in training set
Top 0.4%
1.2%
17
Nature Communications
4913 papers in training set
Top 58%
1.0%
18
iScience
1063 papers in training set
Top 26%
0.9%
19
PLOS ONE
4510 papers in training set
Top 64%
0.9%
20
The Journal of Physical Chemistry B
158 papers in training set
Top 2%
0.9%
21
Nature Nanotechnology
30 papers in training set
Top 1.0%
0.8%
22
Pharmaceutics
21 papers in training set
Top 0.4%
0.8%
23
Communications Chemistry
39 papers in training set
Top 1%
0.8%
24
Frontiers in Plant Science
240 papers in training set
Top 5%
0.8%
25
Analytica Chimica Acta
17 papers in training set
Top 0.6%
0.8%
26
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.8%
27
Integrative Biology
13 papers in training set
Top 0.2%
0.7%
28
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
29
ACS Synthetic Biology
256 papers in training set
Top 3%
0.7%
30
Journal of Nanobiotechnology
10 papers in training set
Top 0.3%
0.7%